3rd Dec 2018 13:13
LONDON (Alliance News) - Creo Medical Group PLC on Monday said the first patient in continental Europe was treated using its Speedboat device.
Speedboat is an electrosurgical platform that combines bipolar radiofrequency for precise, localised cutting and microwave for controlled coagulation.
Creo Medical shares were trading 9.0% higher on Monday at 194.00 pence each.
The medical device company said the patient with a large pre-cancerous lesion in the lower gastrointestinal tract was treated at the Hospital Universitario Virgin del Rocio de Sevilla in Spain.
Patients have now been treated using the Speedboat device powered by Creo's CROMA platform in the UK, South Africa and mainland Europe, the company highlighted.
Looking forward, Creo Medical said it expects to continue to increase the number of trained clinicians in these regions and beyond as the roll-out of the Creo Clinical Education Programme gathers pace.
in addition, Creo Medical said it remains on track with the establishment of a training-centric commercialisation programme in the US.
"Mainland Europe and the US are key markets for the company, and the successful completion of the first procedure in Spain is an important milestone as we roll-out our Clinical Education Programme across Europe initially through our distribution partners covering Spain, the Netherlands, Belgium and Luxembourg," said Creo Medical Chief Executive Craig Gulliford.
Related Shares:
Creo Medical